Engineered immune cells take aim at Tough-to-Treat blood cancer
Disease control
Recruiting now
This first-in-human study is testing a new type of CAR-T cell therapy called Senza5 CART5 for patients with aggressive T-cell lymphoma that has returned or resisted standard treatments. Researchers will give 30 participants a single infusion of these specially modified immune cel…
Phase: PHASE1 • Sponsor: Vittoria Biotherapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC